Inhibikase Therapeutics (IKT) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Surrozen (SRZN) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 99.2% versus a gain of 15.1%. Over five years, SRZN leads with a -70.5% price change compared with -83.5% for IKT. Surrozen is the larger company by market cap ($349.0 million vs $274.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | SRZN |
|---|---|---|
| Share price | $1.97 | $29.69 |
| Market cap | $274.89M | $348.96M |
| 1-day change | +3.14% | +6.15% |
| YTD return | -6.83% | +23.76% |
| 1-year return | +15.06% | +99.22% |
| 5-year return | -83.51% | -70.50% |
| EPS (TTM) | $-0.43 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $37.83 |
| 52-week low | $1.33 | $11.39 |
| Distance from 52-week high | -24.52% | -21.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +204.57% | +63.02% |
| Average volume | 652.84K | 483.28K |
| Shares outstanding | 139.54M | 11.75M |
| Employees | 35 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed IKT by 84.2 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
IKT vs SRZN FAQ
Which is bigger, Inhibikase Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $348.96M compared with $274.89M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, IKT or SRZN?
SRZN returned +99.22% over the past 12 months, compared with +15.06% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.